Annual report pursuant to Section 13 and 15(d)

Revenues from Contracts and Significant Customers

v3.23.1
Revenues from Contracts and Significant Customers
12 Months Ended
Dec. 31, 2022
Revenues from Contracts and Significant Customers  
Revenues from Contracts and Significant Customers

20. Revenues from Contracts and Significant Customers

Disaggregation of Total Revenues

All of Journey’s product revenues are recorded in the U.S. The Company’s collaboration revenue is from Cyprium’s agreement with Sentynl (see Note 3). The Company’s related party revenue is from Checkpoint’s collaborations with TGTX (see Note 17).

The table below summarizes the Company’s revenue for the years ended December 31, 2022 and 2021:

Year Ended December 31, 

    

2022

    

2021

Revenue

Qbrexza®

$

26,715

$

17,056

Accutane®

18,373

10,053

Amzeeq®

7,242

Targadox®

7,972

22,378

Ximino®

4,957

8,247

Zilxi®

2,273

Exelderm®

3,463

5,363

Other branded revenue

37

Collaboration revenue

1,882

5,389

Revenue – related party

 

192

 

268

Other revenue1

2,674

 

Net revenue

$

75,743

$

68,791

Note 1:

Other revenue for the year ended December 31, 2022 included a net $2.5 million milestone payment from Maruho Co., Ltd, upon receipt of marketing and manufacturing approval for Rapifort® Wipes 2.5% (Qbrexza®), as well as $0.2 million in royalties from Maruho on sales of Rapifort® Wipes 2.5% in Japan.

Significant Customers

For the years ended December 31, 2022, none of Journey’s Dermatology Products customers accounted for more than 10.0% of its total gross product revenue.

At December 31, 2022, two of Journey’s customers accounted for more than 10% of its total accounts receivable balance at 16.3% and 12.9%.  As of December 31, 2021, one of the Company’s Dermatology Products customers accounted for 12% of its total accounts receivable balance.